What is the share price of Hester Biosciences Ltd (HESTERBIO) today?
The share price of HESTERBIO as on 4th February 2026 is ₹1523.60. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Hester Biosciences Ltd (HESTERBIO) share?
The past returns of Hester Biosciences Ltd (HESTERBIO) share are- Past 1 week: 8.57%
- Past 1 month: -6.31%
- Past 3 months: -7.73%
- Past 6 months: -29.01%
- Past 1 year: -20.91%
- Past 3 years: -17.56%
- Past 5 years: -11.71%
What are the peers or stocks similar to Hester Biosciences Ltd (HESTERBIO)?
The peers or stocks similar to Hester Biosciences Ltd (HESTERBIO) include:What is the dividend yield % of Hester Biosciences Ltd (HESTERBIO) share?
The current dividend yield of Hester Biosciences Ltd (HESTERBIO) is 0.47.What is the market cap of Hester Biosciences Ltd (HESTERBIO) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Hester Biosciences Ltd (HESTERBIO) is ₹1279.18 Cr as of 4th February 2026.What is the 52 week high and low of Hester Biosciences Ltd (HESTERBIO) share?
The 52-week high of Hester Biosciences Ltd (HESTERBIO) is ₹2350 and the 52-week low is ₹1242.95.What is the PE and PB ratio of Hester Biosciences Ltd (HESTERBIO) stock?
The P/E (price-to-earnings) ratio of Hester Biosciences Ltd (HESTERBIO) is 46.55. The P/B (price-to-book) ratio is 3.92.Which sector does Hester Biosciences Ltd (HESTERBIO) belong to?
Hester Biosciences Ltd (HESTERBIO) belongs to the Health Care sector & Biotechnology sub-sector.How to buy Hester Biosciences Ltd (HESTERBIO) shares?
You can directly buy Hester Biosciences Ltd (HESTERBIO) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Hester Biosciences Ltd
HESTERBIO Share Price
1,523.601.32% (+19.90)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
HESTERBIO Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
HESTERBIO Performance & Key Metrics
HESTERBIO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 31.24 | 3.92 | 0.47% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.50 | 5.64 | 0.61% |
HESTERBIO Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
HESTERBIO Company Profile
Hester Biosciences Limited is engaged in manufacturing of poultry vaccines and large animal vaccines, and trading of poultry health products and large animal health products. Its segments include Poultry Division and Large Animal Division.
BIOCON
PE Ratio
59.50
59.50
1Y Return
2.15%
2.15%
Buy Reco %
76.47
76.47
ANTHEM
PE Ratio
75.59
75.59
1Y Return
16.83%
16.83%
Buy Reco %
75.00
75.00
SAILIFE
PE Ratio
109.15
109.15
1Y Return
28.46%
28.46%
Buy Reco %
100.00
100.00
ACUTAAS
PE Ratio
101.60
101.60
1Y Return
59.41%
59.41%
Buy Reco %
100.00
100.00
ONESOURCE
PE Ratio
-751.55
-751.55
1Y Return
21.44%
21.44%
Buy Reco %
100.00
100.00
HESTERBIO Sentiment Analysis
HESTERBIO Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
HESTERBIO Stock Summary · February 2026
In Q3 FY26, the company demonstrated resilience with a 12% revenue growth, primarily driven by a robust 32% increase in its Poultry Healthcare division, despite facing a 5% revenue decline over the first nine months. Operational efficiency initiatives and strategic investments are expected to sustain profitability, even as the Animal Healthcare division grapples with a 38% drop due to delays in immunization programs. The recent regulatory approval for the H9N2 Avian Influenza vaccine enhances market opportunities, particularly in poultry and petcare, where growth potential remains strong. Management's focus on long-term innovation and direct sales strategies aims to mitigate seasonal fluctuations and reduce reliance on tender-based revenues, positioning the company for future success.
HESTERBIO Stock Growth Drivers
HESTERBIO Stock Growth Drivers
6Strong Financial Performance
Hester Biosciences Limited reported a 12% revenue growth in Q3 FY '26 and a significant
Regulatory Milestones and Product Development
The company achieved a significant regulatory milestone by obtaining marketing and manufacturing licenses for its
HESTERBIO Stock Challenges
HESTERBIO Stock Challenges
3Decline in Animal Healthcare Performance
The Animal Healthcare division has experienced a significant decline in performance, with a 38% drop
Challenges from Seasonal Factors and Cost Pressures
The Ruminant business is facing challenges from seasonal factors, including a lower incidence of clinical
HESTERBIO Forecast
HESTERBIO Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
HESTERBIO
HESTERBIO
Income
Balance Sheet
Cash Flow
Annual Normal View
HESTERBIO Income Statement
HESTERBIO Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 123.53 | 138.49 | 185.28 | 189.64 | 219.01 | 249.17 | 285.65 | 319.80 | 319.12 | 326.01 | ||||||||||
Raw Materials | 29.11 | 35.39 | 41.92 | 44.15 | 46.63 | 75.41 | 82.74 | 87.14 | 81.55 | 242.90 | ||||||||||
| Power & Fuel Cost | 5.59 | 6.37 | 7.83 | 8.13 | 7.57 | 10.28 | 12.74 | 15.30 | 13.98 | |||||||||||
| Employee Cost | 18.32 | 23.24 | 28.93 | 40.65 | 38.92 | 45.33 | 56.02 | 64.13 | 62.42 | |||||||||||
| Selling & Administrative Expenses | 15.93 | 17.92 | 24.99 | 37.78 | 35.47 | 40.18 | 54.77 | 53.21 | 59.06 | |||||||||||
| Operating & Other expenses | 13.15 | 5.75 | 6.36 | -2.85 | 20.41 | 3.82 | 9.22 | 31.12 | 33.05 | |||||||||||
EBITDA | 41.43 | 49.82 | 75.25 | 61.78 | 70.01 | 74.15 | 70.16 | 68.90 | 69.06 | 83.11 | ||||||||||
| Depreciation/Amortization | 7.00 | 9.66 | 11.76 | 13.07 | 13.31 | 16.58 | 20.70 | 17.17 | 16.80 | 17.14 | ||||||||||
| PBIT | 34.43 | 40.16 | 63.49 | 48.71 | 56.70 | 57.57 | 49.46 | 51.73 | 52.26 | 65.97 | ||||||||||
| Interest & Other Items | 3.50 | 4.04 | 6.63 | 7.37 | 6.60 | 4.06 | 9.32 | 19.78 | 12.70 | 11.46 | ||||||||||
| PBT | 30.93 | 36.12 | 56.86 | 41.34 | 50.10 | 53.51 | 40.14 | 31.95 | 39.56 | 54.51 | ||||||||||
| Taxes & Other Items | 7.38 | 10.51 | 15.29 | 12.16 | 15.68 | 14.17 | 13.53 | 13.07 | 12.08 | 13.56 | ||||||||||
| Net Income | 23.55 | 25.61 | 41.57 | 29.18 | 34.42 | 39.34 | 26.61 | 18.88 | 27.48 | 40.95 | ||||||||||
| EPS | 27.68 | 30.11 | 48.87 | 34.30 | 40.46 | 46.25 | 31.28 | 22.19 | 32.30 | 48.14 | ||||||||||
| DPS | 5.30 | 10.00 | 11.00 | 6.60 | 10.00 | 10.00 | 8.00 | 6.00 | 7.00 | 7.00 | ||||||||||
| Payout ratio | 0.19 | 0.33 | 0.23 | 0.19 | 0.25 | 0.22 | 0.26 | 0.27 | 0.22 | 0.15 |
HESTERBIO Company Updates
HESTERBIO Stock Peers
HESTERBIO Past Performance & Peer Comparison
HESTERBIO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Hester Biosciences Ltd | 46.55 | 3.92 | 0.47% |
| Biocon Ltd | 59.50 | 2.18 | 0.10% |
| Anthem Biosciences Ltd | 75.59 | 14.16 | — |
| Sai Life Sciences Ltd | 109.15 | 8.73 | — |
HESTERBIO Stock Price Comparison
Compare HESTERBIO with any stock or ETFCompare HESTERBIO with any stock or ETF
HESTERBIO
HESTERBIO Holdings
HESTERBIO Shareholdings
HESTERBIO Promoter Holdings Trend
HESTERBIO Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
HESTERBIO Institutional Holdings Trend
HESTERBIO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
HESTERBIO Shareholding Pattern
HESTERBIO Shareholding Pattern
HESTERBIO Shareholding History
HESTERBIO Shareholding History
Foreign Institutions
Mutual Funds Invested in HESTERBIO
Mutual Funds Invested in HESTERBIO
No mutual funds holding trends are available
Top 2 Mutual Funds holding Hester Biosciences Ltd
| Funds (Top 2) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0006% | Percentage of the fund’s portfolio invested in the stock 0.05% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 100/123 (-7) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0000% | Percentage of the fund’s portfolio invested in the stock 0.00% | Change in the portfolio weight of the stock over the last 3 months -0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 936/1042 (-3) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing HESTERBIO stock
smallcases containing HESTERBIO stock
Looks like this stock is not in any smallcase yet.
HESTERBIO Events
HESTERBIO Events
HESTERBIO Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
HESTERBIO has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.47%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹4.66 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
HESTERBIO Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
HESTERBIO has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.47%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹4.66 every year
HESTERBIO Upcoming Dividends
HESTERBIO Upcoming Dividends
No upcoming dividends are available
HESTERBIO Past Dividends
HESTERBIO Past Dividends
Cash Dividend
Ex DateEx DateAug 6, 2025
Final
Final | Div/Share: ₹7.00
Dividend/Share
₹7.00
Ex DateEx Date
Aug 6, 2025
Cash Dividend
Ex DateEx DateAug 22, 2024
Final
Final | Div/Share: ₹6.00
Dividend/Share
₹6.00
Ex DateEx Date
Aug 22, 2024
Cash Dividend
Ex DateEx DateSep 13, 2023
Final
Final | Div/Share: ₹8.00
Dividend/Share
₹8.00
Ex DateEx Date
Sep 13, 2023
Cash Dividend
Ex DateEx DateAug 11, 2022
Final
Final | Div/Share: ₹10.00
Dividend/Share
₹10.00
Ex DateEx Date
Aug 11, 2022
Cash Dividend
Ex DateEx DateAug 5, 2021
Final
Final | Div/Share: ₹10.00
Dividend/Share
₹10.00
Ex DateEx Date
Aug 5, 2021
HESTERBIO Stock News & Opinions
HESTERBIO Stock News & Opinions
Articles & Videos
Earnings
Hester Biosciences consolidated net profit declines 24.79% in the December 2025 quarter
Net profit of Hester Biosciences declined 24.79% to Rs 8.77 crore in the quarter ended December 2025 as against Rs 11.66 crore during the previous quarter ended December 2024. Sales rose 22.46% to Rs 77.42 crore in the quarter ended December 2025 as against Rs 63.22 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales77.4263.22 22 OPM %22.998.02 - PBDT17.9617.66 2 PBT13.5213.37 1 NP8.7711.66 -25 Powered by Capital Market - Live
4 days agoCapital Market - Live
Corporate
Hester Biosciences to announce Quarterly Result
Hester Biosciences will hold a meeting of the Board of Directors of the Company on 30 January 2026.Powered by Capital Market - Live
1 week agoCapital Market - Live
Spotlight
Hester Biosciences appoints Ashish Desai as CFO
Ashish Desai, Group Finance Controller at Hester Biosciences, is a Chartered Accountant with over 25 years of experience in accounting, finance, auditing, costing, and taxation. He has driven key initiatives in financial restructuring, treasury management, trade finance, and cost optimization, while strengthening systems and internal controls. Before joining Hester, he served as CFO at Blue Ray Aviation and previously held senior finance roles at Shreeyam Power & Steel Industries and other organizations. Hester Biosciences is one of the leading animal health care companies & the second-largest poultry vaccine manufacturer in India. The company's consolidated net profit surged 76.2% to Rs 14.45 crore on a 15.2% drop in revenue from operations to Rs 70.97 crore in Q2 FY26 over Q2 FY25. Shares of Hester Biosciences rose 0.59% to Rs 1,672 on the BSE.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Hester Biosciences appoints Ashish Desai as CFO
Hester Biosciences announced the appointment of Ashish Desai as Chief Financial Officer and Key Managerial Personnel of the Company (categorised as Senior Management Personnel), presently serving as Group Finance Controller will assume the role of Chief Financial Officer of the Company with effect from 20 November 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Hester Biosciences consolidated net profit rises 76.22% in the September 2025 quarter
Net profit of Hester Biosciences rose 76.22% to Rs 14.45 crore in the quarter ended September 2025 as against Rs 8.20 crore during the previous quarter ended September 2024. Sales declined 15.20% to Rs 70.97 crore in the quarter ended September 2025 as against Rs 83.69 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales70.9783.69 -15 OPM %16.5122.89 - PBDT21.3916.07 33 PBT17.0411.87 44 NP14.458.20 76 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Hester Biosciences announces board meeting date
Hester Biosciences will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Hester Biosciences consolidated net profit rises 159.31% in the June 2025 quarter
Net profit of Hester Biosciences rose 159.31% to Rs 16.44 crore in the quarter ended June 2025 as against Rs 6.34 crore during the previous quarter ended June 2024. Sales rose 2.24% to Rs 84.11 crore in the quarter ended June 2025 as against Rs 82.27 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales84.1182.27 2 OPM %27.1221.45 - PBDT24.3714.73 65 PBT20.1910.59 91 NP16.446.34 159 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Hester Biosciences to announce Quarterly Result
Hester Biosciences will hold a meeting of the Board of Directors of the Company on 1 August 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Hester Biosciences fixes record date for final dividend
Hester Biosciences has fixed 06 August 2025 as record date to determine the members entitled to receive the proposed final dividend of Rs 7 per equity share (i.e. 70% of the face value of Rs 10 each). Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Hester Biosciences AGM scheduled
Hester Biosciences announced that the 38th Annual General Meeting(AGM) of the company will be held on 13 August 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 10.97%, vs industry avg of 21.23%
Over the last 5 years, market share decreased from 2.08% to 1.34%
Over the last 5 years, net income has grown at a yearly rate of -1.19%, vs industry avg of 23.38%